CKD患者肾小管健康与不良事件关联研究
在SPRINT试验2377例合并CKD的高血压患者中,基线检测8种尿肾小管标志物与2种血清矿物质代谢标志物。中位随访3.8年,30%患者发生预设严重不良事件复合终点。NGAL、MCP-1升高与UMOD降低独立于eGFR和白蛋白尿与复合不良事件风险升高相关。
要点
- 尿NGAL、MCP-1升高及UMOD降低与CKD患者不良事件风险独立相关。
- 上述关联独立于eGFR和白蛋白尿,且不随降压治疗分组变化。
- 肾小管标志物或可用于高血压治疗中不良事件的风险分层。
核心结论
- 在合并CKD的高血压患者中,多种肾小管生物标志物与治疗期间不良事件风险升高相关,且独立于eGFR和白蛋白尿。
研究设计与样本
- SPRINT试验中2377例合并CKD的参与者,基线检测8种尿肾小管标志物和2种血清矿物质代谢标志物,采用Cox比例风险模型分析。
- 基线平均年龄73±9岁,平均eGFR 46±11 mL/min/1.73 m2,中位随访3.8年。
主要发现
- 随访期间716例(30%)发生预设严重不良事件复合终点。
- 多变量校正(含eGFR和白蛋白尿)后,尿IL-18、KIM-1、NGAL、MCP-1升高及尿UMOD降低、血清FGF-23升高分别与复合不良事件风险升高相关。
- 联合模型中,NGAL每升高2倍HR=1.08(95%CI 1.03-1.13),MCP-1 HR=1.11(95%CI 1.03-1.19),UMOD HR=0.91(95%CI 0.85-0.97)。
- 生物标志物与不良事件的关联不随干预分组变化(所有交互作用P>0.10)。
关键数值与推荐
- 复合不良事件包括低血压、晕厥、电解质异常、AKI、心动过缓和跌倒致伤;门诊不良事件包括高钾血症和低钾血症。
- 联合模型中NGAL每升高2倍HR=1.08(95%CI 1.03-1.13),MCP-1 HR=1.11(95%CI 1.03-1.19),UMOD HR=0.91(95%CI 0.85-0.97)。
临床怎么用
- 对合并CKD的高血压患者,可考虑检测尿NGAL、MCP-1和UMOD辅助识别不良事件高风险者。
- 肾小管标志物可补充eGFR和白蛋白尿之外的风险信息,但尚不能替代现有评估。
局限性
- 原文摘要未报告检测方法、标志物阈值及队列外推性等局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Measures of kidney tubule health are risk markers for acute kidney injury (AKI) in persons with chronic kidney disease (CKD) during hypertension treatment, but their associations with other adverse events (AEs) are unknown. METHODS: Among 2377 Systolic Blood Pressure Intervention Trial (SPRINT) participants with CKD, we measured at baseline eight urine biomarkers of kidney tubule health and two serum biomarkers of mineral metabolism pathways that act on the kidney tubules. Cox proportional hazards models were used to evaluate biomarker associations with risk of a composite of pre-specified serious AEs (hypotension, syncope, electrolyte abnormalities, AKI, bradycardia and injurious falls) and outpatient AEs (hyperkalemia and hypokalemia). RESULTS: At baseline, the mean age was 73 ± 9 years and mean estimated glomerular filtration rate (eGFR) was 46 ± 11 mL/min/1.73 m2. During a median follow-up of 3.8 years, 716 (30%) participants experienced the composite AE. Higher urine interleukin-18, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin (NGAL) and monocyte chemoattractant protein-1 (MCP-1), lower urine uromodulin (UMOD) and higher serum fibroblast growth factor-23 were individually associated with higher risk of the composite AE outcome in multivariable-adjusted models including eGFR and albuminuria. When modeling biomarkers in combination, higher NGAL [hazard ratio (HR) = 1.08 per 2-fold higher biomarker level, 95% confidence interval (CI) 1.03-1.13], higher MCP-1 (HR = 1.11, 95% CI 1.03-1.19) and lower UMOD (HR = 0.91, 95% CI 0.85-0.97) were each associated with higher composite AE risk. Biomarker associations did not vary by intervention arm (P > 0.10 for all interactions). CONCLUSIONS: Among persons with CKD, several kidney tubule biomarkers are associated with higher risk of AEs during hypertension treatment, independent of eGFR and albuminuria.
引用
- Ascher SB, Scherzer R, Estrella MM, et al. Kidney tubule health, mineral metabolism and adverse events in persons with CKD in SPRINT. Nephrol Dial Transplant. 2022. PMID: 34473302. doi:10.1093/ndt/gfab255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。